Exscientia (NASDAQ:EXAI) Trading Down 8.2%

Exscientia plc (NASDAQ:EXAIGet Rating) shares dropped 8.2% during trading on Friday . The stock traded as low as $6.25 and last traded at $6.39. Approximately 40,979 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 285,029 shares. The stock had previously closed at $6.96.

Exscientia Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.55 and a quick ratio of 7.55. The company has a 50-day moving average price of $7.04 and a 200 day moving average price of $6.93.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Platinum Investment Management Ltd. increased its holdings in shares of Exscientia by 43.6% in the fourth quarter. Platinum Investment Management Ltd. now owns 4,035,934 shares of the company’s stock valued at $21,512,000 after purchasing an additional 1,224,814 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Exscientia in the fourth quarter valued at about $4,280,000. Farallon Capital Management LLC purchased a new stake in shares of Exscientia in the third quarter worth about $3,284,000. Sectoral Asset Management Inc. purchased a new stake in shares of Exscientia in the fourth quarter worth about $1,413,000. Finally, Laurion Capital Management LP boosted its stake in shares of Exscientia by 10.8% in the fourth quarter. Laurion Capital Management LP now owns 2,363,363 shares of the company’s stock worth $12,597,000 after buying an additional 231,209 shares during the last quarter. 22.36% of the stock is owned by institutional investors and hedge funds.

Exscientia Company Profile

(Get Rating)

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.

See Also

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.